Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background Riluzole is the only drug to prolong survival for amyotrophic lateral sclerosis (ALS) and, at a dose of 100 mg, was associated with a 35% reduction in mortality in a clinical trial. A key question is whether the survival benefit occurs at an early stage of disease, late stage, or is spread throughout the course of the disease. To address this question, we used the King's clinical staging system to do a retrospective analysis of data from the original dose-ranging clinical trial of riluzole. Methods In the original dose-ranging trial, patients were enrolled between December, 1992, and November, 1993, in Belgium, France, Germany, Spain, Canada, the USA, and the UK if they had probable or definite ALS as defined by the El Escorial criteria. The censor date for the riluzole survival data was set as the original study end date of Dec 31, 1994. For this analysis, King's clinical ALS stage was estimated from the electronic case record data of the modified Norris scale, UK Medical Research Council score for muscle strength, El Escorial category, vital capacity, and gastrostomy insertion data. The lowest allocated stage was 2 because the original trial only included patients with probable or definite ALS. We used a χ 2 test to assess the independence of stage at trial enrolment and treatment group, Kaplan-Meier product limit distribution to test the transition from each stage to subsequent stages, and Cox regression to confirm an effect of treatment group on time in stage, controlling for covariates. We did sensitivity analyses by combining treatment groups, using alternative strategies to stage, stratifying by stage at trial enrolment, and using multistate outcome analysis of treatments (MOAT). Findings We analysed the case records of all 959 participants from the original dose-ranging trial, 237 assigned to 50 mg/day riluzole, 236 to 100 mg/day, 244 to 200 mg/day, and 242 to daily placebo. Clinical stage at enrolment did not significantly differ between treatment groups (p=0·22). Time in stage 4 was longer for patients receiving 100 mg/day riluzole than for those receiving placebo (hazard ratio [HR] 0·55, 95% CI 0·36–0·83; log-rank p=0·037). Combining treatment groups and stratifying by stage at enrolment showed a similar result (HR 0·638, 95% CI 0·464–0·878; p=0·006), as did analysis with MOAT where the mean number of days spent in stage 4 was numerically higher for patients given riluzole at higher doses compared with patients receiving placebo. Time from stages 2 or 3 to subsequent stages or death did not differ between riluzole treatment groups and placebo (p=0·83 for stage 2 and 0·88 for stage 3). Interpretation We showed that riluzole prolongs survival in the last clinical stage of ALS; this finding needs to be confirmed in a prospective study, and treatment effects at stage 1 still need to be analysed. The ALS stage at which benefit occurs is important for counselling of patients before starting treatment. Staging should be used in future ALS clinical trials to assess the stage at which survival benefit occurs, and a similar approach could be used for other neurodegenerative diseases. Funding NIHR Maudsley Biomedical Research Centre, The European Union Joint Programme on Neurodegeneration, and the King's Summer Undergraduate Studentship.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Current therapeutic options yield minimal benefit in broad patient populations2–4”
From Examining iPSC derived motor neuron variability and genome stability monitoring as a solution (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Self-citationProlonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,318
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis/Riluzole Study Group II, Lacomblez, L., Bensimon, G., Meininger, V, Leigh, P. N., & Guillet, P. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91680-3 · Cited by 1,301
Self-citationA proposed staging system for amyotrophic lateral sclerosis
Roche, J. C., Rojas-Garcia, R., Scott, K. M., Scotton, W., Ellis, C. E., Burman, R., Wijesekera, L., Turner, M. R., Leigh, P. N., Shaw, C. E., et al. (2012) · Brain · doi:10.1093/brain/awr351 · Cited by 465
Self-citationAmyotrophic lateral sclerosis: moving towards a new classification system
Al-Chalabi, A., Hardiman, O., Kiernan, M. C., Chiò, A., Rix-Brooks, B., & van den Berg, L. H. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30199-5 · Cited by 390
Self-citationCzaplinski, A. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072660 · Cited by 273
Pathophysiological and diagnostic implications of cortical dysfunction in ALS
Geevasinga, N., Menon, P., Özdinler, P. H., Kiernan, M. C., & Vucic, S. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.140 · Cited by 234
Cudkowicz, M. E., van den Berg, L. H., Shefner, J. M., Mitsumoto, H., Mora, J. S., Ludolph, A., Hardiman, O., Bozik, M. E., Ingersoll, E. W., Archibald, D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70221-7 · Cited by 233
Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis
Chiò, A., Hammond, E. R., Mora, G., Bonito, V., & Filippini, G. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306589 · Cited by 206
Cited by
Feldman, E. L., Goutman, S. A., Petri, S., Mazzini, L., Savelieff, M. G., Shaw, P. J., & Sobue, G. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01272-7 · Cited by 1,129
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
Jaiswal, M. K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21528 · Cited by 451
Improving clinical trial outcomes in amyotrophic lateral sclerosis
Kiernan, M. C., Vucic, S., Talbot, K., McDermott, C. J., Hardiman, O., Shefner, J. M., Al-Chalabi, A., Huynh, W., Cudkowicz, M., Talman, P., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00434-z · Cited by 291
Self-citationLogroscino, G., Piccininni, M., Marin, B., Nichols, E., Abd-Allah, F., Abdelalim, A., Alahdab, F., Asgedom, S. W., Awasthi, A., Chaiah, Y., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30404-6 · Cited by 272
The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients
Zeng, Q., Shen, J., Chen, K., Zhou, J., Liao, Q., Lu, K., Yuan, J., & Bi, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-69845-8 · Cited by 127
Metadata
- Authors
- Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A.
- Affiliations
- King's College London (GB)
- Brighton and Sussex Medical School (GB)
- Pitié-Salpêtrière Hospital (FR)
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 17
- Issue
- 5
- Pages
- 416-422
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC5899963
- OpenAlex
- W2790800342
- Cited by
- 259
- References
- 32
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 39 · 2023: 33 · 2022: 41 · 2021: 33 · 2020: 38 · 2019: 18 · 2018: 13
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Neurology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by)
- Funders
- Horizon 2020 Framework Programme (633413)
- EU Joint Programme – Neurodegenerative Disease Research
- NIHR Maudsley Biomedical Research Centre
- Medical Research Council (MR/L501529/1)
- Economic and Social Research Council (ES/L008238/1)
- Sanofi
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- amyotrophic lateral sclerosis, riluzole, disease stage, survival benefit, disease progression, treatment effect heterogeneity, dose-response relationship, mortality reduction, El Escorial criteria, gastrostomy, muscle strength, vital capacity, disease-modifying therapy
- MeSH terms
- Amyotrophic Lateral Sclerosis, Dose-Response Relationship, Drug, Humans, Retrospective Studies, Severity of Illness Index, Time Factors, Survival Analysis, Outcome Assessment, Health Care, Disease Progression, Excitatory Amino Acid Antagonists, Riluzole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. https://app.cochat.ai/papers/10.1016/s1474-4422(18)30054-1
- The paper
- Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(18)30054-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.